par de Azambuja, Evandro 
;Bedard, Philippe L;Suter, T.;Piccart-Gebhart, Martine
Référence Targeted oncology, 4, 2, page (77-88)
Publication Publié, 2009-04
;Bedard, Philippe L;Suter, T.;Piccart-Gebhart, Martine Référence Targeted oncology, 4, 2, page (77-88)
Publication Publié, 2009-04
Article révisé par les pairs
| Résumé : | Trastuzumab, a monoclonal antibody that blocks HER-2 receptor, improves the survival of women with HER-2-positive early and advanced breast cancer when given with chemotherapy. Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2, is approved for the treatment of metastatic breast cancer patients after failure of prior anthracycline, taxanes and trastuzumab therapies in combination with capecitabine. Importantly, cardiac toxicity, manifested as symptomatic congestive heart failure or asymptomatic left ventricular ejection fraction decline, has been reported in some of the patients receiving these novel anti-HER-2 therapies, particularly when these drugs are used following anthracyclines, whose cardiotoxic potential has been recognized for decades. This review will focus on the incidence, natural history, underlying mechanisms, management, and areas of uncertainty regarding trastuzumab-and lapatinib-induced cardiotoxicity. |
